Trump cuts drug price deal with Regeneron

President Trump announced a drug pricing deal with Regeneron, the 17th pharmaceutical company to agree to his 'most favored nation' policy, lowering prices for Medicaid and cash-paying patients. Critics question the impact of the confidential agreements, as discounts may not affect most Americans on private insurance or Medicare.